Figure 3.
Comparative survival for patients with PRE/POD6 by second-line treatment. Figure PFS (A) and OS (B) from first progression of disease by salvage treatment category. BTKi, either as a single agent or in combination with other treatments; Lena, treatment with lenalidomide and/or bortezomib, either as a single agent or in combination with other treatments.

Comparative survival for patients with PRE/POD6 by second-line treatment. Figure PFS (A) and OS (B) from first progression of disease by salvage treatment category. BTKi, either as a single agent or in combination with other treatments; Lena, treatment with lenalidomide and/or bortezomib, either as a single agent or in combination with other treatments.

Close Modal

or Create an Account

Close Modal
Close Modal